Results 101 to 110 of about 357,788 (307)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

TIMP4 as a Potential Complementary Biomarker and Therapeutic Target in Membranous Nephropathy: A Multi-Omics Investigation with Clinical Validation

Journal of Inflammation Research
Qingsong Chen, Gang Wang, Ruo Zhao, Qiyuan Hu, Jiayun Li, Yuting Wang, Jingyang Ran, Qi Huang, Guiquan Yu, Yanjia Luo, Xiaohui Liao Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ...
Chen Q, Wang G, Zhao R, Hu Q, Li J, Wang Y, Ran J, Huang Q, Yu G, Luo Y, Liao X   +10 more
doaj  

Tacrolimus exposure during pregnancy in kidney and liver transplantation recipients: A comparison between whole blood and plasma concentration‐to‐dose ratios

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tacrolimus monitoring is generally performed in whole blood (WB). Most (>85%) of circulating tacrolimus is bound to red blood cells. During pregnancy, WB monitoring might be suboptimal because of physiological changes including increased plasma volume and decreased haematocrit.
Jildau R. Meinderts, Paola Mian, Frederike G. I. van Vilsteren, Karien M. H. van de Wetering, Jelmer R. Prins, Stefan P. Berger, Daan J. Touw, Margriet F. C. de Jong   +7 more
wiley   +1 more source

Network Pharmacology Analysis and Machine-Learning Models Confirmed the Ability of YiShen HuoXue Decoction to Alleviate Renal Fibrosis by Inhibiting Pyroptosis [Retraction]

Drug Design, Development and Therapy
Feng M, Luo F, Wu H, et al. Drug Des Devel Ther. 2023;17:3169—3192. https://doi.org/10.2147/DDDT.S420135 We, the Editor and Publisher of Drug Design, Development and Therapy, have retracted the published article.
Feng M, Luo F, Wu H, Chen Y, Zuo J, Weng X, Chen G, Zhong J   +7 more
doaj  

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Supplementum 266: Abstracts of the 54th Annual Meeting of the Swiss Society of Nephrology

Swiss Medical Weekly, 2022
Swiss Society of Nephrology
doaj   +1 more source

Clinician's attitudes & perspective on chemical adherence testing in hypertension (CATCH): A qualitative interview study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Chemical Adherence Testing (CAT) is gaining prominence as a reliable and valid clinical method to detect whether antihypertensive agents are being taken as prescribed. This study aimed to explore clinicians' attitudes and perspectives on the clinical use of CAT.
Roshan Shahab, Louise Rabbitt, Gerard J. Molloy   +2 more
wiley   +1 more source

Digital diagnostics, biomarkers and therapeutics in an evolving healthcare system: From promise to practice

British Journal of Clinical Pharmacology, EarlyView.
Abstract Health care is shifting towards a digital‐guided system, integrating digital diagnostics, biomarkers and therapeutics in many care pathways. However, despite rapid technological advancement and preliminary adoption accelerated by the COVID‐19 pandemic, a significant implementation gap persists. This narrative review explores the causes of this
Mees H. P. Stoop, Gertjan J. A. Driessen, Adam F. Cohen, Matthijs D. Kruizinga   +3 more
wiley   +1 more source

Contraindicated drug–drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval, Sylvain Goutelle, Inesse Boussaha, Xavier Dode, Yanis Mimouni, Kim An Nguyen, Behrouz Kassai   +6 more
wiley   +1 more source

Supplementum 275: Abstracts of the 55th Annual meeting of the Swiss Society of Nephrology

Swiss Medical Weekly, 2022
Swiss Society of Nephrology
doaj   +1 more source